Atorvastatin for Cardiovascular Risk After Hypertensive Disorders of Pregnancy
This study is looking at whether a medication called Atorvastatin (10 mg) can help reduce your risk of heart disease after you've experienced a hypertensive disorder of pregnancy (like gestational hypertension or preeclampsia). Researchers want to see if taking Atorvastatin for three months after breastfeeding stops can lower your 30-year Framingham Risk Score for Cardiovascular Disease. You might be able to join if you are a woman between 20 and 50 years old, are postpartum, and have been diagnosed with a hypertensive disorder of pregnancy. The study is currently recruiting 76 participants, but its overall status is unclear.
- Study design
- This is a double-blinded randomized controlled trial, meaning neither you nor your doctor will know if you're receiving Atorvastatin or a placebo. It plans to enroll 76 participants.
- What's involved
- You would take Atorvastatin 10 mg or a placebo daily for 3 months, starting after you stop breastfeeding. You will be followed for up to 1 year.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 1 year after the start of the study treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
AtorvaStatin Postpartum and Reduction of Cardiovascular risK
At a glance
Conditions
NCT06632379
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine
Columbus, Ohiostudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Tracy C Bank, MD · PRINCIPAL_INVESTIGATOR · Ohio State University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- The 30-year Framingham Risk Score for Cardiovascular DiseaseAfter 3 months of study treatment, up to 9 months after enrollment
Predicts 0-100% risk of "hard" CVD events (coronary death, myocardial infarction, stroke) based on sex, systolic blood pressure, antihypertensive treatment, total and high-density lipoprotein cholesterol, smoking, and diabetes mellitus. A higher number reflects a greater risk of adverse CVD events, whereas a lower number reflects lower risk.